The University of MichiganNews & Information services
The University Record¤onine
search Updated: 8:30 a.m.. EDT -- 24 September 2002  
   
front

accolades

news briefs

events

UM employment


obituaries police beat
regents round-up
research reporter
letters



archives

Advertise with Record

contact us

contact us
Artificial liver trials show progress, as transplant
candidates wait

Four years after the first American clinical trial of an experimental artificial liver system began at the U-M Health System (UMHS), its leader says he is encouraged by the results thus far. Dr. Robert Bartlett says he is optimistic about the system's potential to help more liver-failure patients stay alive until they receive a liver transplant or recover without one.

Already, 20 desperately ill patients have used the device in a phase I trial, Bartlett says. Of the six patients who went on to receive a transplant, three are still alive but continue to have liver damage. Two others recovered liver function without needing a transplant.

The system, called albumin dialysis, uses special filters and proteins to remove toxic substances from the blood while sparing helpful compounds.

Results from Germany, where the system was invented, and from the three other American hospitals now testing it, also give Bartlett hope. The system appears safe, able to reduce blood toxins, and able to reverse coma and shock.

Liver transplants offer hope for many people, but there aren't enough organs from deceased and living donors to go around. In 2001, 5,177 Americans received new livers, but another 1,975 died waiting. Nearly 1,000 of the more than 17,460 patients now waiting are children and teenagers.

A new liver transplant candidate system instituted by the United Network for Organ Sharing in 2001 places the sickest patientsácalled status 1áat the top of the list to receive livers as they become available. But that means patients are most likely to receive a liver when they have the least amount of time to wait. Status 1 patients are defined as having fewer than seven days to live. That makes artificial liver support more crucial than ever, Bartlett says.

"Current and future clinical trials will help further establish how well albumin dialysis might help buy time for the 17,400 Americans now waiting for a liver transplant, and the tens of thousands more on waiting lists worldwide," says Bartlett, who is a professor of surgery, director of critical care and head of the extracorporeal life support team at UMHS.

"We must also explore whether the system can help patients regain function in their own livers, as two of our patients did," he says. "Currently, we are using albumin dialysis only for patients in the intensive-care unit who need emergency liver transplants, but we will soon extend the treatment to other patients with liver disease."

U-M is preparing to participate in a multi-center, randomized and controlled trial comparing albumin dialysis with standard medical treatment in chronic liver failure patients who are in hepatic comasáa neurological state caused by liver failure. The new U-M trial, led by U-M gastroenterologist Dr. Robert Fontana, will begin in early 2003.

In addition to Bartlett, other U-M researchers are Dr. Fresca Swaniker, Dr. John Magee, Dr. Jeffrey Punch and Dr. Steve Rudich.


More stories:

 
 


Front Page | Accolades | News Briefs | Events | UM-Employment
Archives | Obituaries | Police beat | Regents Round-up | Research Reporter | Letters | Contact Webmaster

Copyright © 2002 The Regents of the University of Michigan
Ann Arbor, MI 48109 USA 1-734-764-1817